Efficacy and safety of caspofungin in obese patients

References

• Pappas PG, Kauffman, CA, Andes D, . Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503–535.
   PubMed Web of Science ®Google Scholar
• Kartsonis NA, Nielsen J, Douglas CM. Caspofungin: the first in a new class of antifungal agents. Drug Resist Update 2003; 6: 197–218.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Adamson PC, Seibel NL, . Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005; 49: 4536–4545.
   PubMed Web of Science ®Google Scholar
• Villanueva A, Arathoon EG, Gotuzzo E, . A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33: 1533–1535.
   Google Scholar
• Arathoon EG, Gotuzzo E, Noriega LM, . Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2002; 46: 451–457.
   PubMed Web of Science ®Google Scholar
• DiNubile MJ, Lupinacci RJ, Berman R, Sable CA. Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin. AIDS Res Human Retrovir 2002; 18: 903–908.
   PubMed Web of Science ®Google Scholar
• Villanueva A, Gotuzzo E, Arathoon EG, . A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113: 294–299.
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C, . Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020–2029.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Lasso M, Betts R, . Caspofungin for treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007; 60: 363–369.
   PubMed Web of Science ®Google Scholar
• Betts RF, Nucci M, Talwar D, . A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48: 1676–1684.
   PubMed Web of Science ®Google Scholar
• Maertens J, Raad I, Petrikkos G, . Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563–1571.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR, . Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391–1402.
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex JH, de Pauw B, . Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14.
   PubMed Web of Science ®Google Scholar
• Stone JA, Xu X, Winchell GA, . Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004; 48: 815–823.
   PubMed Web of Science ®Google Scholar
• Stone JA, Holland SD, Wickersham PJ, . Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46: 739–745.
   PubMed Web of Science ®Google Scholar
• Nguyen TH, Hoppe-Tichy T, Geiss HK, . Factors influencing caspofungin plasma concentration in patients of a surgical intensive care unit. J Antimicrob Chemother 2007; 60: 100–106.
   PubMed Web of Science ®Google Scholar
• Gumbo T, Hiemenz J, Ma L, Keirns JJ, . Population pharmacokinetics of micafungin in adult patients. Diag Micrbiol Infect 2008; 60: 329–331.
   PubMed Web of Science ®Google Scholar
• Dowell JA, Knebal W, Ludden T, . Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004; 44: 590–598.
   PubMed Web of Science ®Google Scholar
• Lagakos SW. The challenge of subgroup analyses – reporting without distorting. N Engl J Med 2006; 354: 1667–1669.
   PubMed Web of Science ®Google Scholar
• Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine reporting of subgroup analyses in clinical trials. N Engl J Med 2007; 357: 2189–2194.
   PubMed Web of Science ®Google Scholar